Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs

Ming Jie Li, Gerhard Bauer, Alessandro Michienzi, Jiing Kuan Yee, Nan Sook Lee, James Kim, Shirley Li, Daniela Castanotto, John Zaia, John J. Rossi

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

A primary advantage of lentiviral vectors is their ability to pass through the nuclear envelope into the cell nucleus thereby allowing transduction of nondividing cells. Using HIV-based lentiviral vectors, we delivered an anti-CCR5 ribozyme (CCR5RZ), a nucleolar localizing TAR RNA decoy, or Pol III-expressed siRNA genes into cultured and primary cells. The CCR5RZ is driven by the adenoviral VA1 Pol III promoter, while the human U6 snRNA Pol III-transcribed TAR decoy is embedded in a U16 snoRNA (designated U16TAR), and the siRNAs were expressed from the human U6 Pol III promoter. The transduction efficiencies of these vectors ranged from 96-98% in 293 cells to 15-20% in primary PBMCs. A combination of the CCR5RZ and U16TAR decoy in a single vector backbone gave enhanced protection against HIV-1 challenge in a selective survival assay in both primary T cells and CD34+-derived monocytes. The lentiviral vector backbone-expressed siRNAs also showed potent inhibition of p24 expression in PBMCs challenged with HIV-1. Overall our results demonstrate that the lentiviral-based vectors can efficiently deliver single constructs as well as combinations of Pol III therapeutic expression units into primary hematopoietic cells for anti-HIV gene therapy and hold promise for stem or T-cell-based gene therapy for HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)196-206
Number of pages11
JournalMolecular Therapy
Volume8
Issue number2
DOIs
StatePublished - Aug 1 2003
Externally publishedYes

Fingerprint

Catalytic RNA
HIV Infections
HIV-1
HIV
RNA
Genetic Therapy
Small Nucleolar RNA
T-Lymphocytes
Nuclear Envelope
Cell Nucleus
Small Interfering RNA
Monocytes
Cultured Cells
Survival
Genes
Therapeutics

Keywords

  • CCR5
  • HIV-1 gene therapy
  • Lentiviral vector
  • Ribozyme
  • RNA decoy
  • siRNAs
  • TAR

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. / Li, Ming Jie; Bauer, Gerhard; Michienzi, Alessandro; Yee, Jiing Kuan; Lee, Nan Sook; Kim, James; Li, Shirley; Castanotto, Daniela; Zaia, John; Rossi, John J.

In: Molecular Therapy, Vol. 8, No. 2, 01.08.2003, p. 196-206.

Research output: Contribution to journalArticle

Li, MJ, Bauer, G, Michienzi, A, Yee, JK, Lee, NS, Kim, J, Li, S, Castanotto, D, Zaia, J & Rossi, JJ 2003, 'Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs', Molecular Therapy, vol. 8, no. 2, pp. 196-206. https://doi.org/10.1016/S1525-0016(03)00165-5
Li, Ming Jie ; Bauer, Gerhard ; Michienzi, Alessandro ; Yee, Jiing Kuan ; Lee, Nan Sook ; Kim, James ; Li, Shirley ; Castanotto, Daniela ; Zaia, John ; Rossi, John J. / Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs. In: Molecular Therapy. 2003 ; Vol. 8, No. 2. pp. 196-206.
@article{78cff5a1f9294c56adb6c374b3ceda46,
title = "Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs",
abstract = "A primary advantage of lentiviral vectors is their ability to pass through the nuclear envelope into the cell nucleus thereby allowing transduction of nondividing cells. Using HIV-based lentiviral vectors, we delivered an anti-CCR5 ribozyme (CCR5RZ), a nucleolar localizing TAR RNA decoy, or Pol III-expressed siRNA genes into cultured and primary cells. The CCR5RZ is driven by the adenoviral VA1 Pol III promoter, while the human U6 snRNA Pol III-transcribed TAR decoy is embedded in a U16 snoRNA (designated U16TAR), and the siRNAs were expressed from the human U6 Pol III promoter. The transduction efficiencies of these vectors ranged from 96-98{\%} in 293 cells to 15-20{\%} in primary PBMCs. A combination of the CCR5RZ and U16TAR decoy in a single vector backbone gave enhanced protection against HIV-1 challenge in a selective survival assay in both primary T cells and CD34+-derived monocytes. The lentiviral vector backbone-expressed siRNAs also showed potent inhibition of p24 expression in PBMCs challenged with HIV-1. Overall our results demonstrate that the lentiviral-based vectors can efficiently deliver single constructs as well as combinations of Pol III therapeutic expression units into primary hematopoietic cells for anti-HIV gene therapy and hold promise for stem or T-cell-based gene therapy for HIV-1 infection.",
keywords = "CCR5, HIV-1 gene therapy, Lentiviral vector, Ribozyme, RNA decoy, siRNAs, TAR",
author = "Li, {Ming Jie} and Gerhard Bauer and Alessandro Michienzi and Yee, {Jiing Kuan} and Lee, {Nan Sook} and James Kim and Shirley Li and Daniela Castanotto and John Zaia and Rossi, {John J.}",
year = "2003",
month = "8",
day = "1",
doi = "10.1016/S1525-0016(03)00165-5",
language = "English (US)",
volume = "8",
pages = "196--206",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Inhibition of HIV-1 infection by lentiviral vectors expressing Pol III-promoted anti-HIV RNAs

AU - Li, Ming Jie

AU - Bauer, Gerhard

AU - Michienzi, Alessandro

AU - Yee, Jiing Kuan

AU - Lee, Nan Sook

AU - Kim, James

AU - Li, Shirley

AU - Castanotto, Daniela

AU - Zaia, John

AU - Rossi, John J.

PY - 2003/8/1

Y1 - 2003/8/1

N2 - A primary advantage of lentiviral vectors is their ability to pass through the nuclear envelope into the cell nucleus thereby allowing transduction of nondividing cells. Using HIV-based lentiviral vectors, we delivered an anti-CCR5 ribozyme (CCR5RZ), a nucleolar localizing TAR RNA decoy, or Pol III-expressed siRNA genes into cultured and primary cells. The CCR5RZ is driven by the adenoviral VA1 Pol III promoter, while the human U6 snRNA Pol III-transcribed TAR decoy is embedded in a U16 snoRNA (designated U16TAR), and the siRNAs were expressed from the human U6 Pol III promoter. The transduction efficiencies of these vectors ranged from 96-98% in 293 cells to 15-20% in primary PBMCs. A combination of the CCR5RZ and U16TAR decoy in a single vector backbone gave enhanced protection against HIV-1 challenge in a selective survival assay in both primary T cells and CD34+-derived monocytes. The lentiviral vector backbone-expressed siRNAs also showed potent inhibition of p24 expression in PBMCs challenged with HIV-1. Overall our results demonstrate that the lentiviral-based vectors can efficiently deliver single constructs as well as combinations of Pol III therapeutic expression units into primary hematopoietic cells for anti-HIV gene therapy and hold promise for stem or T-cell-based gene therapy for HIV-1 infection.

AB - A primary advantage of lentiviral vectors is their ability to pass through the nuclear envelope into the cell nucleus thereby allowing transduction of nondividing cells. Using HIV-based lentiviral vectors, we delivered an anti-CCR5 ribozyme (CCR5RZ), a nucleolar localizing TAR RNA decoy, or Pol III-expressed siRNA genes into cultured and primary cells. The CCR5RZ is driven by the adenoviral VA1 Pol III promoter, while the human U6 snRNA Pol III-transcribed TAR decoy is embedded in a U16 snoRNA (designated U16TAR), and the siRNAs were expressed from the human U6 Pol III promoter. The transduction efficiencies of these vectors ranged from 96-98% in 293 cells to 15-20% in primary PBMCs. A combination of the CCR5RZ and U16TAR decoy in a single vector backbone gave enhanced protection against HIV-1 challenge in a selective survival assay in both primary T cells and CD34+-derived monocytes. The lentiviral vector backbone-expressed siRNAs also showed potent inhibition of p24 expression in PBMCs challenged with HIV-1. Overall our results demonstrate that the lentiviral-based vectors can efficiently deliver single constructs as well as combinations of Pol III therapeutic expression units into primary hematopoietic cells for anti-HIV gene therapy and hold promise for stem or T-cell-based gene therapy for HIV-1 infection.

KW - CCR5

KW - HIV-1 gene therapy

KW - Lentiviral vector

KW - Ribozyme

KW - RNA decoy

KW - siRNAs

KW - TAR

UR - http://www.scopus.com/inward/record.url?scp=10744228940&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=10744228940&partnerID=8YFLogxK

U2 - 10.1016/S1525-0016(03)00165-5

DO - 10.1016/S1525-0016(03)00165-5

M3 - Article

VL - 8

SP - 196

EP - 206

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 2

ER -